A detailed history of Lazard Asset Management LLC transactions in Axogen, Inc. stock. As of the latest transaction made, Lazard Asset Management LLC holds 12,243 shares of AXGN stock, worth $180,461. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,243
Previous 12,517 2.19%
Holding current value
$180,461
Previous $90,000 90.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$7.52 - $14.69 $2,060 - $4,025
-274 Reduced 2.19%
12,243 $171,000
Q2 2024

Aug 14, 2024

BUY
$5.67 - $8.06 $5,545 - $7,882
978 Added 8.48%
12,517 $90,000
Q1 2024

May 14, 2024

BUY
$6.63 - $10.69 $17,708 - $28,552
2,671 Added 30.12%
11,539 $93,000
Q4 2023

Feb 14, 2024

BUY
$3.61 - $7.76 $32,013 - $68,815
8,868 New
8,868 $60,000
Q2 2023

Aug 14, 2023

BUY
$8.5 - $10.38 $60,426 - $73,791
7,109 New
7,109 $64,000
Q2 2022

Aug 09, 2022

BUY
$6.99 - $10.0 $13,043 - $18,660
1,866 Added 36.67%
6,954 $56,000
Q1 2022

May 13, 2022

BUY
$7.26 - $10.7 $34,267 - $50,504
4,720 Added 1282.61%
5,088 $40,000
Q4 2021

Feb 09, 2022

SELL
$8.8 - $16.0 $21,903 - $39,824
-2,489 Reduced 87.12%
368 $3,000
Q3 2021

Nov 15, 2021

SELL
$15.23 - $21.72 $3,548 - $5,060
-233 Reduced 7.54%
2,857 $45,000
Q4 2020

Feb 11, 2021

BUY
$11.5 - $17.96 $25,024 - $39,080
2,176 Added 238.07%
3,090 $55,000
Q2 2020

Aug 13, 2020

BUY
$7.35 - $10.81 $6,717 - $9,880
914 New
914 $8,000
Q2 2018

Aug 13, 2018

SELL
$36.15 - $52.5 $607,536 - $882,315
-16,806 Closed
0 $0
Q1 2018

May 14, 2018

SELL
$24.4 - $40.25 $160,942 - $265,489
-6,596 Reduced 28.19%
16,806 $613,000
Q4 2017

Feb 13, 2018

BUY
$18.5 - $28.6 $432,937 - $669,297
23,402
23,402 $662,000

Others Institutions Holding AXGN

About Axogen, Inc.


  • Ticker AXGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 42,283,700
  • Market Cap $623M
  • Description
  • AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...
More about AXGN
Track This Portfolio

Track Lazard Asset Management LLC Portfolio

Follow Lazard Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lazard Asset Management LLC with notifications on news.